


PHARMACEUTICAL 2019

Xencor Inc Rank 33 of 363









PHARMACEUTICAL 2019



Xencor Inc Rank 33 of 363



The relative strengths and weaknesses of Xencor Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xencor Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 41% points. The greatest weakness of Xencor Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 5.5% points.

The company's Economic Capital Ratio, given in the ranking table, is 262%, being 225% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	315,727
Cost of Goods Sold	0
Intangible Assets	11,969
Liabilities, Current	53,853
Liabilities, Non-Current	0
Other Assets	237,223
Other Compr. Net Income	837
Other Expenses	0
Other Liabilities	1,198
Other Net Income	8,961
Other Revenues	40,603
Property and Equipment	11,813
Research and Development	97,501
Selling, General and Administrative Expense	22,472

Output Variable	Value in 1000 USD
Assets	576,732
Liabilities	55,051
Expenses	119,973
Revenues	40,603
Stockholders Equity	521,681
Net Income	-70,409
Comprehensive Net Income	-69,990
Economic Capital Ratio	262%

